Highlights on datopotamab deruxtecan in advanced NSCLC: The TROPION-Lung01 study

Valemetostat and datopotamab deruxtecan in advanced NSCLCПодробнее

TROPION-Lung01 & TROPION-Lung05: datopotamab deruxtecan for NSCLCПодробнее

Ongoing studies for datopotamab deruxtecan in NSCLCПодробнее

TROPION-PanTumor03: datopotamab deruxtecan in advanced solid tumorsПодробнее

BEGONIA: datopotamab deruxtecan and durvalumab in metastatic triple-negative breast cancerПодробнее

Efficacy of datopotamab deruxtecan, a TROP2 ADC, in aNSCLCПодробнее

TROPION-PanTumor01: datopotamab deruxtecan in advanced HER2+ breast cancerПодробнее

Addressing Key Targets in Advanced NSCLC: HER2-, HER3-, and TROP2-Targeted TherapiesПодробнее

Patritumab deruxtecan shows promise for EGFR inhibitor-resistant NSCLC | Pasi JänneПодробнее

Antibody drug conjugates in lung cancerПодробнее

ESMO 2023 Lung Cancer Highlights – Keynote 671 | ALINA | TropionLung01 | Oncology BrothersПодробнее

Trastuzumab Deruxtecan for HER2-Mutated Metastatic NSCLCПодробнее

BEGONIA: durvalumab + dato-DXd in advanced TNBCПодробнее

DESTINY-Lung01: cohort expansion resultsПодробнее

Dato-DXd: a new ADC on the blockПодробнее